Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0006498
UniProt IDP41743
Primary gene name(s)PRKCI
Synonym gene name(s)DXS1179E
Protein nameProtein kinase C iota type
Protein functionCalcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase, PI(3K and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer, NSCLC cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor, NGF, acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters, VTCs. In human coronary artery endothelial cells, HCAEC, is activated by saturated fatty acids and mediates lipid-induced apoptosis. {ECO:0000269|PubMed:10356400, ECO:0000269|PubMed:10467349, ECO:0000269|PubMed:10906326, ECO:0000269|PubMed:11042363, ECO:0000269|PubMed:11724794, ECO:0000269|PubMed:12871960, ECO:0000269|PubMed:14684752, ECO:0000269|PubMed:15994303, ECO:0000269|PubMed:18270268, ECO:0000269|PubMed:19327373, ECO:0000269|PubMed:21189248, ECO:0000269|PubMed:21419810, ECO:0000269|PubMed:8226978, ECO:0000269|PubMed:9346882}.
Subcellular locationCytoplasm {ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:9566925}. Membrane {ECO:0000269|PubMed:16452474}. Endosome {ECO:0000269|PubMed:9566925}. Nucleus {ECO:0000269|PubMed:11891849, ECO:0000269|PubMed:15695176}. Note=Transported into the endosome through interaction with SQSTM1/p62. After phosphorylation by SRC, transported into the nucleus through interaction with KPNB1. Colocalizes with CDK7 in the cytoplasm and nucleus. Transported to vesicular tubular clusters, VTCs through interaction with RAB2A. {ECO:0000269|PubMed:15695176, ECO:0000269|PubMed:9566925}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: P41743
Gene Ontology
(Biological Process)
Complete annatation
actin filament organization [GO:0007015];
bicellular tight junction assembly [GO:0070830];
cell-cell junction organization [GO:0045216];
cell migration [GO:0016477];
cellular response to insulin stimulus [GO:0032869];
cytoskeleton organization [GO:0007010];
establishment of apical/basal cell polarity [GO:0035089];
establishment or maintenance of epithelial cell apical/basal polarity [GO:0045197];
eye photoreceptor cell development [GO:0042462];
Golgi vesicle budding [GO:0048194];
intracellular signal transduction [GO:0035556];
membrane organization [GO:0061024];
negative regulation of apoptotic process [GO:0043066];
negative regulation of glial cell apoptotic process [GO:0034351];
negative regulation of neuron apoptotic process [GO:0043524];
peptidyl-serine phosphorylation [GO:0018105];
positive regulation of endothelial cell apoptotic process [GO:2000353];
positive regulation of establishment of protein localization to plasma membrane [GO:0090004];
positive regulation of glial cell proliferation [GO:0060252];
positive regulation of glucose import [GO:0046326];
positive regulation of neuron projection development [GO:0010976];
positive regulation of NF-kappaB transcription factor activity [GO:0051092];
protein phosphorylation [GO:0006468];
protein targeting to membrane [GO:0006612];
response to interleukin-1 [GO:0070555];
secretion [GO:0046903];
vesicle-mediated transport [GO:0016192]
Gene Ontology
(Molecular Function)
Complete annatation
ATP binding [GO:0005524];
metal ion binding [GO:0046872];
phospholipid binding [GO:0005543];
protein kinase activity [GO:0004672];
protein kinase C activity [GO:0004697];
protein serine/threonine kinase activity [GO:0004674]
Gene Ontology
(Cellular Component)
Complete annatation
apical plasma membrane [GO:0016324];
bicellular tight junction [GO:0005923];
cell leading edge [GO:0031252];
cytoplasm [GO:0005737];
cytosol [GO:0005829];
endosome [GO:0005768];
extracellular exosome [GO:0070062];
Golgi membrane [GO:0000139];
intercellular bridge [GO:0045171];
microtubule cytoskeleton [GO:0015630];
nucleus [GO:0005634];
plasma membrane [GO:0005886];
protein complex [GO:0043234];
Schmidt-Lanterman incisure [GO:0043220]
Protein-protein interaction111570
Phylogenetic treeP41743
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD30.06147818915664160.8512940263506270.900716290990287
AZA vs. DISU0.3431747084196740.1792183946961050.764658387107016
AZA vs. IL7-0.02525789346963290.8962131720186460.999311006273513
AZA vs. SAHA0.3280128322491910.1816612247850570.544514078824807
DISU vs. CD30.2679550849812240.461542036815550.590802026406047
DISU vs. IL7-0.3767710531449960.137696557634660.485542188041558
DISU vs. SAHA-0.01433151560936190.9614917094909580.992101982318104
DMSO vs. AZA-0.1188067074573150.4827057704902761
DMSO vs. CD3-0.1923468439647660.5483831223636970.652507048290743
DMSO vs. DISU-0.4638782872849070.06039913960362430.474317370415122
DMSO vs. IL70.1007092148597190.5785815245242780.905672503991634
DMSO vs. SAHA0.4394699751596640.06411431489037490.292708944869797
HIV vs. Mock in Activation-0.008625283935693450.9889476449136320.999983755607037
HIV vs. Mock in Latency-0.00663159015881980.9682423407674780.999834320637052
IL7 vs. CD3-0.07776405629239150.8088948983014220.875713898343957
SAHA vs. CD30.2406103492707740.4986662114542040.607657459902552
SAHA vs. IL70.3491145683982040.155377872030010.373909010692907
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) unknown
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.208085 0.148014
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
0.895 1.236 1.354 1.436 1.315
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB03777 Rbt205 Inhibitor experimental unknown unknown
DB00675 Tamoxifen approved unknown unknown

Protein Secondary Structure       (annotations from PDB)      top

PDB Accession Method Resolution Chain Structure Preview
1VD2 NMR - A=25-108.
1WMH X-ray 1.5Å A=25-108.
1ZRZ X-ray 3.0Å A=233-596.
3A8W X-ray 2.1Å A/B=249-588.
3A8X X-ray 2.0Å A/B=249-588.
3ZH8 X-ray 2.7Å A/B/C=248-594.
5LI1 X-ray 2.0Å A=248-596.
5LI9 X-ray 1.7Å A=248-596.
5LIH X-ray 3.2Å A/B=248-596.

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 interacts with 11141237
115049231970444
22114277
3259291
8599832
Vpr regulated by 24447338
Tat activates 8627654
9446795
9671211
10843712
11044099
11154208
11833470
11919157
12482669
Envelope transmembrane glycoprotein gp41 inhibits 1832084
21396767850771
Tat phosphorylated by 8914829
21651489
Pr55(Gag) interacts with 24447338
Pr55(Gag) binds 24447338
Pr55(Gag) phosphorylated by 24447338
matrix phosphorylated by 7876252
8473314
9151826
21651489
Envelope surface glycoprotein gp160; precursor interacts with 7642615
retropepsin inhibited by 10491200
reverse transcriptase phosphorylated by 10641798
Tat cooperates with 20336759
Tat regulated by 2182321
18577246
Envelope surface glycoprotein gp120 upregulates 24162774
8206685
Envelope surface glycoprotein gp120 activates 19363595
Envelope surface glycoprotein gp120 regulated by 15689238

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa04015 Rap1 signaling pathway - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04390 Hippo signaling pathway - Homo sapiens (human)
hsa04530 Tight junction - Homo sapiens (human)
hsa04611 Platelet activation - Homo sapiens (human)
hsa04910 Insulin signaling pathway - Homo sapiens (human)
Menu